Redx Pharma Plc (LON:REDX)

Redx Pharma Plc (LON:REDX)


Share Price
5.35 p
Change
0 (0.00 %)
Market Cap
£6.77 m
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc

Focused on the development of novel medicines to validated anti-cancer and fibrosis targets in areas of unmet need

Redx Pharma uses its proven drug discovery expertise to generate development candidates that it will take into the clinic and then partner. The company’s product development strategy has three interrelated components:

Cancer: RXC004, our lead clinical asset
Build on...

EPIC: REDX
Market: AIM:REDX
52-week High/Low: 11.445p / 4.750p
Sector: Pharma & Biotech
Market Cap: £6.77 m
Website: www.redxpharma.com
col 3
col 4
col 5
col 6

Lisa Anson, chief executive of Redx Pharma Plc (LON:REDX), pitches the company to investors. For more information visit www.redxpharma.com

Big Picture – A Deep Dive Examination of Redx Pharma Plc


Redx Pharma Plc Snapshot

Drug discovery and development business creating high value cancer and fibrosis therapeutics

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class.

Ian Ross, Chairman
Iain Ross was appointed Non-Executive Chairman of Redx in May 2017 assuming the role of Executive Chairman in October 2017. In addition, he is Chairman of e-Therapeutics plc (AIM:ETX) and Novogen Ltd (ASX: NRT / NASDAQ:NVGN) and also a Non-Executive Director of Anatara LifeSciences Ltd (ASX:ANR). He is a qualified Chartered Director, and a Former Vice Chairman of the Council of Royal Holloway, London University.

Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc. He has advised banks and private equity groups on numerous company turnarounds. These include as CEO of Quadrant Healthcare taking the Company public, signing numerous collaborations before selling the business to Elan in 2001. As Chairman and Chief Executive Officer, at Allergy Therapeutics, he re-structured the Company Balance Sheet to position Allergy Therapeutics as a virtually debt free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics Plc (formerly SR Pharma plc), he turned the business around through M&A and established collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc. He continues to consult for private equity groups on biotech & technology company turnarounds.


Lisa Anson, Chief Executive Offier
Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed 1 June 2018.

Lisa has been President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Lisa has held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams.

Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. Upon graduating she joined KPMG in London as a management consultant and then moved to California where she worked for Salick Health Care (now Aptium), a California based cancer disease management company, prior to joining Zeneca Pharmaceuticals (USA) in 1998 as a business development manager.

Lisa is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government.


Dr Bernhard Kirschbaum, Non-Executive Director

Bernhard Kirschbaum joined the Board in January 2016. Bernhard has over 25 years’ experience in pharmaceutical research and drug development, having held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel. He has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. In the eight years to 2013, he worked at Merck/Merck Serono, becoming a member of the Board and Executive Vice-President, Global Research & Early Development. He was responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company’s R&D portfolio, with over 70 programs, doubling the number of phase II assets in this period. Dr Kirschbaum is currently Chairman of Protagen Diagnostics and a board member of BioMedX and OMEICOS Therapeutics.


Peter Presland, Non-executive Director

Peter Presland has nearly 45 years’ experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King’s College, London, he also qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc, a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the youngest ever PLC Director when appointed Group Finance Director at the age of 34. He was promoted to become Heath’s Group Chief Executive in 1990, and in 1996, he devised the demerger of C E Heath’s computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Executive Chairman. Shareholders doubled their money in three years. Since 2001, Peter has pursued a portfolio non-executive career. These appointments include the Chairmanship in 2003 of LINK, the UK ATM network, where he led a major corporate governance change and completed the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. From 2012 to 2015, he served as Chairman of the Audit and Governance Committee of East Kent Hospitals NHS Trust and has recently joined the Audit, Governance and Nominations Committee of The Lord’s Taverners, a high-profile charity.

 

James Mead, Chief Financial Officer

James was appointed on 1st February 2019. James has held a variety of highly relevant Finance leadership roles over a 16 year career with AstraZeneca Plc. As Chief Financial Officer of AstraZeneca Netherlands – a $200 million turnover business – he was a core member of a management team accountable for delivery of stretching annual P&L targets and other balanced scorecard objectives during a period of significant change. As R&D Portfolio Finance Director he was responsible for financial analysis of the entire R&D portfolio in order to support decision-making at the CEO-chaired AZ Portfolio Investment Board. He has been the Finance Director of multiple clinical development project teams, guiding assessment of the valuation impact of key decisions such as clinical trial design, commercial launch strategy and product lifecycle management. Additionally, James has gained capital markets experience through positions in AstraZeneca’s Investor Relations and Corporate Finance teams. James holds a PhD in Molecular Biology and a First Class honours degree in Biochemistry, both awarded by Cardiff University. He is also an Associate Member of the Chartered Institute of Management Accountants.

Redx Pharma Plc
Block 33
Mereside, Alderley Park
Alderley Edge
Macclesfield
SK10 4TG

 

Business Development

Nicholas Adams
Block 33
Mereside
Alderley Park
Macclesfield
SK10 4TG

01625 238 972

 

Investor Relations

Karl Hård
Block 33
Mereside
Alderley Park
Macclesfield
SK10 4TG

+44 7491 651 406

 

Human Resources

Redx Pharma HR
PO Box 707
Wakefield
WF1 9PJ

01924 566 080

 

Financial PR

Consilium Strategic Communications
41 Lothbury
London
EC2R 7HG

020 3709 5700

 

Public Relations

Chris Hulme
Influential
5th Floor, Oxford Place
61 Oxford Street
Manchester
M1 6EQ

0161 804 1400

Nominated Advisor & Broker
Cantor Fitzgerald Europe
One Churchill Place
London E14 5RB, UK

Joint Broker
WG Partners LLP
85 Gresham Street
London EC2V 7NQ, UKAuditor
RSM UK Audit LLP
3 Hardman Street
Manchester M3 3HF, UK

Financial Communications Advisor
FTI Consulting
200 Aldersgate Street
London EC1A 4HD

Legal Advisors
Covington and Burling LLP
265 Strand
London WC2R 1BH, UK

DWF LLP
1 Scott Place
2 Hardman Street
Manchester M3 3AA, UK

Registrar
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA, UK

Columns Including REDX

VIEW ALL

Market Reports Including REDX

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use